Medizinische Fachkraft
Bitte melden Sie sich an, um exklusive Informationen und Services zu erhalten.

AOP Orphan continues to grow based on a long-term strategic direction and through leadership changes. Andreas Steiner has been promoted to CEO of AOP Orphan International AG and Georg Fischer, previous Chief Corporate Scientific Officer succeeds Andreas Steiner as CEO of AOP Orphan Pharmaceuticals GmbH in Vienna.

Vienna, August 26th, 2021. After AOP Orphan announced in mid-July 2021 that its legal form was converted from an AG (joint stock company) to a GmbH (limited liability company), the Austrian rare and special disease specialist now also announced changes within its leadership.

New Group CEO of AOP Orphan International AG: Andreas Steiner

“With this move, I can concentrate even more on the strategic leadership of the AOP Orphan Group. This step will also enable us to invest in research and development more than ever and provide patients with improved comprehensive care in the future. We feel responsible for them, their well-being, and their quality of life. They can rely on us throughout their patient journey“, says Andreas Steiner.

Steiner is an economist by education and has in-depth knowledge of the industry due to his career in the healthcare sector for more than 30 years. He joined AOP Orphan as Chief Financial Officer in 2013 and was appointed Chief Executive Officer in 2018.

Georg Fischer is new Head of AOP Orphan Pharmaceuticals GmbH

After Vienna-based AOP Orphan changed its legal form to a limited liability company, previous Chief Corporate Scientific Officer Dr. Georg Fischer now succeeds Andreas Steiner as the new CEO.

“AOP Orphan expanded rapidly over the past year. After taking over Amomed GmbH and SciPharm s.r.l. in the fall of 2020, AOP Orphan has continued its growth trajectory: our strong presence in Europa has been strengthened even further and our often life-saving therapies have also been made available to patients in Canada and Argentina at the beginning of this year. Furthermore, we have just taken the first step into the US market. We expect that our US partner business can start in 2023 and will come with annual contribution margin increases of up to 15%, provided the agreement will obtain US regulatory clearance. Despite this international growth, we continue to produce 80% of our products in Europe,” states Georg Fischer, who will manage the business of AOP Orphan in Vienna from now on.

Fischer is a medical doctor with qualifications in pharmacology from the Austrian Medical Association.  Prior to joining the pharmaceutical industry nearly 30 years ago, he worked in basic research and as a hospital physician. His pharmaceutical career ranges from clinical research, medical affairs, manufacturing, marketing & selling to business development.

AOP Orphan Pharmaceuticals GmbH is an international pharmaceutical company focused on rare and special diseases. Headquartered in Vienna, Austria, with subsidiaries and representative offices across Europe, the Middle East and Northern Africa, the company has become an established provider of integrated therapy solutions over the past 25 years. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other - especially patients and their families, but also the doctors and care professionals treating them. In the third quarter of 2020, AOP Orphan took over Amomed Pharma GmbH and SciPharm s.r.l., two European health care companies, continuing its consistent path of growth into a pan-European health care group specializing in rare and special diseases.